Longwood Capital Partners
Latest statistics and disclosures from Acuta Capital Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are OCUL, INSM, TRML, CRNX, ELVN, and represent 36.38% of Acuta Capital Partners's stock portfolio.
- Added to shares of these 10 stocks: DRUG, TRVI, CDTX, NAMS, ZYME, ELDN, TECX, PRAX, LQDA, SGMO.
- Started 8 new stock positions in FBRX, SGMO, ZYME, NAMS, DRUG, CDTX, CRVS, ELDN.
- Reduced shares in these 10 stocks: PCVX (-$7.4M), ACLX, KURA, CMPS, TSHA, SLRN, MREO, DYN, GILD, GERN.
- Sold out of its positions in SLRN, BNTC, CMPS, CRBP, DYN, CLYM, GERN, KURA, LPTX, TVTX.
- Acuta Capital Partners was a net seller of stock by $-16M.
- Acuta Capital Partners has $99M in assets under management (AUM), dropping by -19.49%.
- Central Index Key (CIK): 0001582844
Tip: Access up to 7 years of quarterly data
Positions held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 39 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ocular Therapeutix (OCUL) | 9.5 | $9.5M | -6% | 1.1M | 8.54 |
|
| Insmed Com Par $.01 (INSM) | 7.3 | $7.2M | -2% | 105k | 69.04 |
|
| Tourmaline Bio (TRML) | 7.2 | $7.1M | +5% | 352k | 20.28 |
|
| Crinetics Pharmaceuticals In (CRNX) | 6.3 | $6.3M | -6% | 123k | 51.13 |
|
| Enliven Therapeutics (ELVN) | 6.1 | $6.0M | -9% | 267k | 22.50 |
|
| Aadi Bioscience (AADI) | 5.9 | $5.8M | 1.8M | 3.15 |
|
|
| Praxis Precision Medicines I (PRAX) | 5.2 | $5.2M | +17% | 68k | 76.96 |
|
| Revolution Medicines (RVMD) | 4.9 | $4.9M | +3% | 112k | 43.74 |
|
| Argenx Se Sponsored Adr (ARGX) | 4.3 | $4.2M | +17% | 6.9k | 615.00 |
|
| Vaxcyte (PCVX) | 3.7 | $3.7M | -66% | 45k | 81.86 |
|
| Trevi Therapeutics (TRVI) | 3.2 | $3.2M | +165% | 772k | 4.12 |
|
| Ascendis Pha- Sponsored Adr (ASND) | 3.2 | $3.2M | +9% | 23k | 137.67 |
|
| Mereo Biopharma Group Pl- Spon Ads (MREO) | 2.7 | $2.7M | -38% | 779k | 3.50 |
|
| Bright Minds Biosciences Com New (DRUG) | 2.5 | $2.5M | NEW | 69k | 36.02 |
|
| Terns Pharmaceuticals (TERN) | 2.5 | $2.5M | -8% | 448k | 5.54 |
|
| Edgewise Therapeutics (EWTX) | 2.4 | $2.3M | +39% | 88k | 26.70 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 1.9 | $1.9M | 181k | 10.50 |
|
|
| Unicycive Therapeutics (UNCY) | 1.8 | $1.8M | +16% | 2.3M | 0.79 |
|
| Rocket Pharmaceuticals (RCKT) | 1.7 | $1.7M | -29% | 135k | 12.57 |
|
| Liquidia Corporation Com New (LQDA) | 1.6 | $1.6M | +87% | 138k | 11.76 |
|
| Mersana Therapeutics (MRSN) | 1.6 | $1.6M | -6% | 1.1M | 1.43 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 1.5 | $1.5M | -58% | 884k | 1.73 |
|
| Tectonic Therapeutic (TECX) | 1.5 | $1.5M | +140% | 33k | 46.17 |
|
| Cidara Therapeutics Com New (CDTX) | 1.5 | $1.5M | NEW | 55k | 26.88 |
|
| Newamsterdam Pharma Co Nv Ordinary Shares (NAMS) | 1.3 | $1.3M | NEW | 50k | 25.70 |
|
| Zymeworks Del (ZYME) | 1.0 | $984k | NEW | 67k | 14.64 |
|
| Eledon Pharmaceuticals #n/a (ELDN) | 1.0 | $971k | NEW | 236k | 4.12 |
|
| Verve Therapeutics (VERV) | 0.9 | $904k | +9% | 160k | 5.64 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.9 | $884k | -16% | 21k | 42.07 |
|
| Gilead Sciences (GILD) | 0.9 | $845k | -53% | 9.2k | 92.37 |
|
| Arcellx Common Stock (ACLX) | 0.8 | $824k | -82% | 11k | 76.69 |
|
| Sangamo Biosciences (SGMO) | 0.8 | $755k | NEW | 740k | 1.02 |
|
| Third Harmonic Bio (THRD) | 0.5 | $512k | +221% | 50k | 10.29 |
|
| Artiva Biotherapeutics (ARTV) | 0.4 | $444k | 44k | 10.08 |
|
|
| Forte Biosciences Com New (FBRX) | 0.4 | $412k | NEW | 18k | 22.71 |
|
| Corvus Pharmaceuticals (CRVS) | 0.4 | $398k | NEW | 74k | 5.35 |
|
| Celcuity (CELC) | 0.3 | $327k | -46% | 25k | 13.09 |
|
| Rapport Therapeutics (RAPP) | 0.3 | $291k | -6% | 16k | 17.74 |
|
| Nuvation Bio Inc -cw27 *w Exp 07/07/2027 (NUVB.WS) | 0.0 | $21k | 91k | 0.23 |
|
Past Filings by Acuta Capital Partners
SEC 13F filings are viewable for Acuta Capital Partners going back to 2014
- Acuta Capital Partners 2024 Q4 filed Feb. 14, 2025
- Acuta Capital Partners 2024 Q3 filed Nov. 14, 2024
- Acuta Capital Partners 2024 Q2 filed Aug. 14, 2024
- Acuta Capital Partners 2024 Q1 filed May 15, 2024
- Acuta Capital Partners 2023 Q4 filed Feb. 14, 2024
- Acuta Capital Partners 2023 Q3 filed Nov. 14, 2023
- Acuta Capital Partners 2023 Q2 filed Aug. 14, 2023
- Acuta Capital Partners 2023 Q1 filed May 15, 2023
- Acuta Capital Partners 2022 Q4 filed Feb. 14, 2023
- Acuta Capital Partners 2022 Q3 filed Nov. 14, 2022
- Acuta Capital Partners 2022 Q2 filed Aug. 15, 2022
- Acuta Capital Partners 2022 Q1 filed May 16, 2022
- Acuta Capital Partners 2021 Q4 filed Feb. 14, 2022
- Acuta Capital Partners 2021 Q3 filed Nov. 15, 2021
- Acuta Capital Partners 2021 Q2 filed Aug. 16, 2021
- Acuta Capital Partners 2021 Q1 filed May 17, 2021